Association of BAX G(-248)A and BCL2 C(-717)A polymorphisms with outcome in diffuse large B-cell lymphoma patients.
Department of Internal Medicine, Faculty of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil.
Angelo B C
ABC
Brito
Haematology and Haemotherapy Centre, University of Campinas, Campinas, São Paulo, Brazil.
Marcia Torresan
MT
Delamain
Department of Internal Medicine, Faculty of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil.
Cristiane
C
de Oliveira
A. C. Camargo Cancer Centre, São Paulo, Brazil.
Marcello Ferreti
MF
Fanelli
A. C. Camargo Cancer Centre, São Paulo, Brazil.
Fernando Augusto
FA
Soares
Department of Internal Medicine, Faculty of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil.|Haematology and Haemotherapy Centre, University of Campinas, Campinas, São Paulo, Brazil.
Cármino A
CA
de Souza
A. C. Camargo Cancer Centre, São Paulo, Brazil.|Laboratory of Molecular and Investigative Pathology, Faculty of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil.
José
J
Vassallo
Department of Internal Medicine, Faculty of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil.
Carmen
C
Silvia Passos Lima
D000483:Alleles; D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005838:Genotype; D006801:Humans; D053208:Kaplan-Meier Estimate; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality* / Q000473:pathology; D008297:Male; D020641:Polymorphism, Single Nucleotide; D011241:Prednisone / Q000009:adverse effects / Q000627:therapeutic use; D011379:Prognosis; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000235:genetics*; D000069283:Rituximab; D016896:Treatment Outcome; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use; D051028:bcl-2-Associated X Protein / Q000235:genetics*
D058846:Antibodies, Monoclonal, Murine-Derived; D019253:Proto-Oncogene Proteins c-bcl-2; C571759:R-CHOP protocol; D051028:bcl-2-Associated X Protein; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone


BAX

; 
BCL2
; Diffuse large B-cell lymphoma; outcome; single nucleotide polymorphism